Other languages Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
0.731 ^USD	+2.55%		+16.46%	-45.85%

30/04	Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	CI
04/04	Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	30/04
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	04/04
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	03/04
Top Midday Decliners	01/04
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	26/02
Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600	08/01
Biora Therapeutics, Inc. Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform with AstraZeneca	02/01
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	21/12
Biora Therapeutics, Inc. Announces New Research Collaboration for the Biojet Systemic Oral Delivery Platform	11/12
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	01/12
Sector Update: Health Care Stocks Steady Pre-Bell Friday	01/12
Top Premarket Gainers	01/12
Biora Therapeutics Says FDA Cleared Application for Investigational Ulcerative Colitis Treatment; Shares Rise Pre-Bell	01/12
Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis	01/12
Biora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Biora Therapeutics to Submit Updated Application to FDA for BT-600	24/23/24
Biora Therapeutics Presents Data on the Biojet? Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes	05/23/05
Biora Therapeutics Shares Rise After BioJet Platform Achieves Performance Target	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Other languages

Filters